Oculis gets FDA clearance to study Privosegtor in acute MS relapses
OCS•The FDA cleared Oculis' investigational new drug application for Privosegtor, enabling clinical development in acute multiple sclerosis relapses.
1. FDA clears application
The FDA cleared Oculis' investigational new drug application for Privosegtor, enabling clinical development in acute multiple sclerosis relapses.
Related News

Essential Properties Realty Trust: Wells Fargo raises target price to $32 from $30
EPRT•

Lithium Americas raises Thacker Pass Phase 1 capital cost estimate to US$3.83 billion
LAC•


